{
    "clinical_study": {
        "@rank": "124265", 
        "arm_group": {
            "arm_group_label": "Experimental Arm", 
            "arm_group_type": "Experimental", 
            "description": "Induction chemotherapy: Cyclophosphamide, Doxorubicin, Vincristine, Etoposide and Prednisone Stem Cell Mobilization/Harvest: filgrastim +/- plerixafor Stem Cell Collection by leukapheresis Conditioning Chemotherapy: gemcitabine, busulfan, melphalan, with palifermin support Autologous stem cell transplantation"
        }, 
        "brief_summary": {
            "textblock": "This is a phase II study of CHOEP induction chemotherapy followed by autologous stem cell\n      transplant using gemcitabine/busulfan/melphalan conditioning in patients with newly\n      diagnosed systemic T-cell non-Hodgkin lymphoma."
        }, 
        "brief_title": "CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "T-cell Non-Hodgkin Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin", 
                "Lymphoma, T-Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a phase II study of CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide and\n      prednisone)induction chemotherapy followed by autologous stem cell transplant using\n      gemcitabine/busulfan/melphalan conditioning in patients with newly diagnosed systemic T-cell\n      non-Hodgkin lymphoma.  The study treatment comprises 6 cycles of CHOEP, followed (for\n      responding patients) by stem cell mobilization and harvesting (using neupogen +/-\n      plerixafor) followed by high dose therapy and autologous stem cell transplantation,"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of T-Cell lymphoma with mandatory pathologic review at Brigham and Women's\n             Hospital or Massachusetts General Hospital\n\n          -  Measurable disease\n\n          -  Candidate for Autologous Stem Cell Transplant\n\n        Exclusion Criteria:\n\n          -  Prior anti-lymphoma chemotherapy (except steroids/radiotherapy for urgent palliation,\n             one prior cycle of CHOP or up to 2 prior cycles of CHOEP)\n\n          -  Pregnant or breastfeeding\n\n          -  Alk-positive ACL\n\n          -  Significant neuropathy precluding vincristine administration\n\n          -  Known hypersensitivity to any of the agents used in the treatment\n\n          -  Uncontrolled intercurrent illness\n\n          -  Receiving other investigational agents\n\n          -  History of a different malignancy except if disease free for at least 5 years or have\n             cervical cancer in situ or basal cell/squamous cell carcinoma of the skin\n\n          -  HIV positive on anti-retroviral therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 4, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01746173", 
            "org_study_id": "12-388"
        }, 
        "intervention": [
            {
                "arm_group_label": "Experimental Arm", 
                "description": "Intravenous, on Day 1, 3 or 6 cycles", 
                "intervention_name": "Cyclophosphamide", 
                "intervention_type": "Drug", 
                "other_name": "cytoxan"
            }, 
            {
                "arm_group_label": "Experimental Arm", 
                "description": "Intravenously, on Day 1, 3 or 6 cycles", 
                "intervention_name": "Doxorubicin", 
                "intervention_type": "Drug", 
                "other_name": "adriamycin"
            }, 
            {
                "arm_group_label": "Experimental Arm", 
                "description": "Intravenously, on Day 1, 3 or 6 cycles", 
                "intervention_name": "Vincristine", 
                "intervention_type": "Drug", 
                "other_name": "oncovin"
            }, 
            {
                "arm_group_label": "Experimental Arm", 
                "description": "Intravenously or orally, Day 1,2 and 3, 3 or 6 cycles", 
                "intervention_name": "Etoposide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Experimental Arm", 
                "description": "Taken orally, days 1-5", 
                "intervention_name": "Prednisone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Experimental Arm", 
                "description": "Subcutaneous daily injection for 5-7 days", 
                "intervention_name": "Filgrastim", 
                "intervention_type": "Drug", 
                "other_name": [
                    "neupogen", 
                    "G-CSF"
                ]
            }, 
            {
                "arm_group_label": "Experimental Arm", 
                "description": "daily subcutaneous injections for 0-2 days", 
                "intervention_name": "Plerixafor", 
                "intervention_type": "Drug", 
                "other_name": "mozobil"
            }, 
            {
                "arm_group_label": "Experimental Arm", 
                "description": "Leukapheresis used to collect stem cells from peripheral blood", 
                "intervention_name": "Stem Cell Collection", 
                "intervention_type": "Procedure", 
                "other_name": "Leukapheresis"
            }, 
            {
                "arm_group_label": "Experimental Arm", 
                "description": "Daily intravenous infusion", 
                "intervention_name": "Palifermin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "KGF", 
                    "kepivance"
                ]
            }, 
            {
                "arm_group_label": "Experimental Arm", 
                "description": "intravenous infusion for 2 days", 
                "intervention_name": "Gemcitabine", 
                "intervention_type": "Drug", 
                "other_name": "gemzaar"
            }, 
            {
                "arm_group_label": "Experimental Arm", 
                "description": "intravenous infusion for 4 days", 
                "intervention_name": "Busulfan", 
                "intervention_type": "Drug", 
                "other_name": "busulfex"
            }, 
            {
                "arm_group_label": "Experimental Arm", 
                "description": "intravenous infusion for 2 days", 
                "intervention_name": "Melphalan", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Experimental Arm", 
                "description": "Reinfusion of stored peripheral blood stem cells", 
                "intervention_name": "Stem Cell Transplant", 
                "intervention_type": "Procedure", 
                "other_name": "Stem Cell Infusion"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Busulfan", 
                "Cyclophosphamide", 
                "Melphalan", 
                "Gemcitabine", 
                "Etoposide phosphate", 
                "Doxorubicin", 
                "Etoposide", 
                "Prednisone", 
                "Vincristine", 
                "Lenograstim", 
                "JM 3100"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "T Cell lymphoma", 
        "lastchanged_date": "February 3, 2014", 
        "location": [
            {
                "contact": {
                    "email": "parmand@partners.org", 
                    "last_name": "Philippe Armand, MD", 
                    "phone": "617-632-2305"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Dana-Farber Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Philippe Armand, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "parmand@partners.org", 
                    "last_name": "Philippe Armand, MD", 
                    "phone": "617-632-2305"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Brigham and Women's Hospital"
                }, 
                "investigator": {
                    "last_name": "Philippe Armand, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Study of CHOEP Induction Followed by Gemcitabine/Busulfan/Melphalan Autologous Stem Cell Transplantation for Patients With Newly Diagnosed T-Cell Lymphoma", 
        "overall_contact": {
            "email": "parmand@partners.org", 
            "last_name": "Philippe Armand, MD", 
            "phone": "6176322305"
        }, 
        "overall_official": {
            "affiliation": "Dana-Farber Cancer Institute", 
            "last_name": "Philippe Armand, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To estimate the proportion of patients alive and progression-free after 24 months after the beginning of CHOEP + Gem/Bu/Mel HDT/ASCT among patients younger than 70 years old with untreated TCL", 
            "measure": "24 month progression-free survival", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01746173"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Dana-Farber Cancer Institute", 
            "investigator_full_name": "Philippe Armand, MD, PhD", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "To estimate the response rate (completed remission [CR] and partial remission [PR]) after CHOEP x 6 and after Gem/Bu/Mel ASCT", 
                "measure": "Response rate", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Overall survival of patients at 2 years", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "To estimate the toxicity (grade 3 and above) with this regimen using CTCAE v4.0.  All grade 3 and above adverse events, and all serious adverse events will be recorded.  This will be reported as number of events and as number of patients with events for all events of interest.", 
                "measure": "Grade 3 and above toxicity related to study regimen", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "description": "To estimate the rate of successful stem cell mobilization after CHOEP in responding patients.", 
                "measure": "Stem cell mobilization rate", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "To estimate the proportion of patients who can successfully complete the entire treatment regimen", 
                "measure": "Proportion of patients who successfully complete regimen", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "To estimate the time to engraftment of neutrophil and platelet engraftment after ASCT", 
                "measure": "Engraftment time", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "To estimate the cumulative incidence of relapse at 24 months", 
                "measure": "Relapse", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "To estimate the cumulative incidence of treatment-related mortality at 24 months", 
                "measure": "Treatment-related mortality", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }
        ], 
        "source": "Dana-Farber Cancer Institute", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Massachusetts General Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Beth Israel Deaconess Medical Center", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Dana-Farber Cancer Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}